

Toleranzia brings forward the publication of the Q2-report for 2025

Toleranzia AB (publ) brings forward the publication of the interim report for the second quarter of 2025 to August 7, 2025, instead of August 29, 2025, as previously announced. The reason for the change is that work on the interim report is expected to be completed earlier than previously planned.

For further information, please contact

Charlotte Fribert - CEO, Toleranzia AB

Tel: +46 763 19 98 98

E-post: charlotte.fribert@toleranzia.com

About Toleranzia AB (publ)

Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed.

Toleranzia's shares are listed on Nasdaq First North Growth Market and Svensk

Kapitalmarknadsgranskning AB, +46 (0)8 913 008, ca@skmg.se, is the company's Certified Adviser.

Attachments

[Toleranzia brings forward the publication of the Q2-report for 2025](#)